Another Blow For Anti-TIGITs As Merck’s Vibostolimab/Keytruda Combo Misses In Phase II NSCLC Trial
But Still Has Potential In Earlier Lines
Merck & Co’s combination treatment has disappointed in a challenging group of lung cancer patients, marking yet another setback for the increasingly precarious anti-TIGIT space even as some analysts say this is not the end of the road.
You may also be interested in...
Novartis declined to option BeiGene’s TIGIT inhibitor, ociperlimab. BeiGene will continue a Phase III study combining it with PD-1 inhibitor tislelizumab while dropping another Phase III.
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.